Oppenheimer initiated coverage on Sagimet Biosciences with a new price target

12/6/24 8:14:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $30.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SGMT

Date	Price Target	Rating	Analyst
12/6/2024	$30.00	Outperform	Oppenheimer
11/12/2024	$12.00	Buy	UBS
6/28/2024	$23.00 → $6.00	Buy → Neutral	Goldman
5/2/2024	$32.00	Buy	H.C. Wainwright
3/25/2024	$26.00	Outperform	Leerink Partners
8/8/2023		Outperform	TD Cowen
8/8/2023	$67.00	Overweight	Piper Sandler
8/8/2023	$33.00	Buy	Goldman